Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Reuters19d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche, which in late 2023 agreed to buy drug developer Carmot ... US Senate confirms Trump's picks to lead FDA, NIH 6:22 PM UTC The dollar hit a three-week high against the euro and gained ...
Nasdaq26d
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
Roche’s shares have risen 30.6% year to date compared with the large ... Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one or more food allergies.
Benzinga.com27d
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
0%), and AEs treated with epinephrine (37.3% vs. 6.9%) were all more common in the OIT group. Also Read: Roche-Prothena Partnered Mid-Stage Parkinson’s Trial Misses Primary Endpoint, But Cling ...